NantHealth (DB:NEL0) - Aandelenkoers, Nieuws & Analyse

NEL0 Overzicht aandelen

Operates as a healthcare IT company in the United States, Canada, and the United Kingdom. Meer informatie

NEL0 fundamentele analyse
Sneeuwvlok Score
Waardering	2/6
Toekomstige groei	0/6
Prestaties in het verleden	0/6
Financiële gezondheid	2/6
Dividenden	0/6

Risicoanalyse

Negatief eigen vermogen

Aandeelhouders zijn het afgelopen jaar substantieel verwaterd

Aandelen zijn zeer illiquide

Heeft geen betekenisvolle marktkapitalisatie ( €13M )

NantHealth, Inc. Concurrenten

MeVis Medical Solutions

XTRA:M3V

€44.4m

DocCheck

XTRA:AJ91

€41.4m

CompuGroup Medical SE KGaA

XTRA:COP

€786.4m

Geratherm Medical

XTRA:GME

€21.0m

Prijsgeschiedenis en prestaties

Overzicht van alle hoogtepunten, veranderingen en prijsdalingen voor NantHealth
Historische aandelenkoersen
Huidige aandelenkoers	US$0.26
52 Week Hoogtepunt	US$5.17
52 Week Laag	US$0.20
Bèta	1.64
11 maand verandering	0%
3 maanden verandering	0%
1 Jaar Verandering	-93.60%
33 jaar verandering	-99.06%
5 jaar verandering	-98.24%
Verandering sinds IPO	-99.86%

Recent nieuws en updates

Recent updates

Rendement voor aandeelhouders

	NEL0	DE Healthcare Services	DE Markt
7D	0%	2.3%	0.8%
1Y	-93.6%	-31.3%	9.1%

Rendement versus industrie: NEL0 presteerde slechter dan de German Healthcare Services -sector, die het afgelopen jaar een rendement van -31.3 % opleverde.

Rendement versus markt: NEL0 presteerde slechter dan German Market, dat het afgelopen jaar een rendement van 9.1 % opleverde.

Prijsvolatiliteit

Is NEL0's price volatile compared to industry and market?
NEL0 volatility
NEL0 Average Weekly Movement	n/a
Healthcare Services Industry Average Movement	5.9%
Market Average Movement	4.8%
10% most volatile stocks in DE Market	10.8%
10% least volatile stocks in DE Market	2.4%

Stabiele aandelenkoers: De aandelenkoers van NEL0 is de afgelopen 3 maanden volatiel geweest.

Volatiliteit in de loop van de tijd: Onvoldoende gegevens om de volatiliteitsverandering van NEL0 in het afgelopen jaar te bepalen.

Over het bedrijf

Opgericht	Werknemers	CEO	Website
2010	373	Rao Naseem	nanthealth.com

NantHealth, Inc. Samenvatting

Hoe verhouden de winst en inkomsten van NantHealth zich tot de beurswaarde?
NEL0 fundamentele statistieken
Marktkapitalisatie	€11.54m
Inkomsten(TTM)	-€63.09m
Inkomsten(TTM)	€62.54m

0.2x

P/S-verhouding

-0.2x

Koers/Winstverhouding

Is NEL0 overgewaardeerd?

Zie Reële waarde en waarderingsanalyse

Inkomsten en omzet

Belangrijkste winstgevendheidsstatistieken uit het laatste winstverslag (TTM)
NEL0 resultatenrekening (TTM)
Inkomsten	US$68.44m
Kosten van inkomsten	US$23.74m
Brutowinst	US$44.69m
Overige uitgaven	US$113.74m
Inkomsten	-US$69.04m

Laatst gerapporteerde inkomsten

Jun 30, 2023

Volgende inkomensdatum

n.v.t.

Winst per aandeel (EPS)	-2.51
Brutomarge	65.31%
Nettowinstmarge	-100.89%
Schuld/Eigen Vermogen Verhouding	-111.3%

Hoe presteerde NEL0 op de lange termijn?

Bekijk historische prestaties en vergelijking

NEL0 Overzicht aandelen

Risicoanalyse

NantHealth, Inc. Concurrenten

XTRA:M3V

€44.4m

XTRA:AJ91

€41.4m

XTRA:COP

€786.4m

XTRA:GME

€21.0m

Prijsgeschiedenis en prestaties

Recent nieuws en updates

NantHealth, Inc Appoints Scott Maratea as Chief Revenue Officer

NantHealth, Inc. Announces the Appointment of Marc Harrison as Chief Legal Officer

NantHealth, Inc. Files Form 15

NantHealth, Inc. Announces the Cessation of Ronald Louks as Chief Operating Officer

NantHealth, Inc. has withdrawn its Follow-on Equity Offering in the amount of $30 million.

NantHealth, Inc. announced delayed 10-Q filing

Recent updates

NantHealth, Inc Appoints Scott Maratea as Chief Revenue Officer

NantHealth, Inc. Announces the Appointment of Marc Harrison as Chief Legal Officer

NantHealth, Inc. Files Form 15

NantHealth, Inc. Announces the Cessation of Ronald Louks as Chief Operating Officer

NantHealth, Inc. has withdrawn its Follow-on Equity Offering in the amount of $30 million.

NantHealth, Inc. announced delayed 10-Q filing

Nanthealth, Inc. Announces Resignation of Deanna L. Wise from Her Position on the Board and as A Member of the Special Committee, the Audit Committee, and the Nominating and Corporate Governance Committee of the Board

Summus Holdings Engages in Discussions with NantHealth

NantHealth, Inc. Announces Executive Changes

Nant Capital Engages in Discussions with NantHealth

Nant Capital Engages in Discussions with NantHealth

NantHealth, Inc. announced delayed 10-Q filing

NantHealth, Inc.(NasdaqGS:NH) dropped from S&P TMI Index

NantHealth Receives Notice from Nasdaq Regarding Non-Compliance with the Minimum Market Value of Publicly Held Shares Requirement

First quarter 2023 earnings released: US$1.59 loss per share (vs US$2.07 loss in 1Q 2022)

NantHealth Receives Written Notice from Nasdaq Stating the Company Has Not Complied with the Public Float Requirement Prior to the Expiration of the Compliance Period

Full year 2022 earnings released: US$8.80 loss per share (vs US$7.66 loss in FY 2021)

Insufficient new directors

Third quarter 2022 earnings released: US$0.12 loss per share (vs US$0.094 loss in 3Q 2021)

NantHealth, Inc. to Report Q3, 2022 Results on Nov 03, 2022

NantHealth, Inc. Receives Written Notice from Nasdaq

Second quarter 2022 earnings released: US$0.11 loss per share (vs US$0.13 loss in 2Q 2021)

NantHealth, Inc. to Report Q2, 2022 Results on Aug 04, 2022

First quarter 2022 earnings released: US$0.14 loss per share (vs US$0.14 loss in 1Q 2021)

NantHealth, Inc. to Report Q1, 2022 Results on May 05, 2022

NantHealth, Inc. Receives Notice from the Nasdaq Stock Market LLC

Full year 2021 earnings: Revenues and EPS in line with analyst expectations

NantHealth, Inc. to Report Q4, 2021 Results on Feb 24, 2022

NantHealth, Inc. Announces Not Stand for Re-Election of Michael S. Sitrick as Member of the Board Directors

Third quarter 2021 earnings released: US$0.094 loss per share (vs US$0.099 loss in 3Q 2020)

Second quarter 2021 earnings released: US$0.13 loss per share (vs US$0.43 loss in 2Q 2020)

First quarter 2021 earnings released: US$0.14 loss per share (vs US$0.081 loss in 1Q 2020)

NantHealth, Inc. Launches Eviti Connect for Autoimmune Diseases

Founder recently bought €4.2m worth of stock

Founder recently bought €4.2m worth of stock

NantHealth, Inc. announced that it expects to receive $137.5 million in funding from Nant Capital, LLC, Highbridge Capital Management, LLC

Chief Operating Officer recently sold €249k worth of stock

Full year 2020 earnings released: US$0.80 loss per share (vs US$0.57 loss in FY 2019)

Revenue misses expectations

NantHealth, Inc. to Report Q4, 2020 Results on Feb 25, 2021

New 90-day high: €3.88

NantHealth, Inc. and Sesame Announces Collaboration to Help Providers Increase Productivity and Better Serve Patients

New 90-day high: €3.41

NantHealth Presents Significant Treatment Insights at the 2020 San Antonio Breast Cancer Symposium in a Time of Need with the Pandemic’s Impact on Cancer Care

NantHealth, Inc. and ImmunityBio Announce RNA Profiling for Clinical Decision Support Publication In Nature’s Scientific Reports

Revenue beats expectations

Third quarter 2020 earnings released: US$0.099 loss per share

New 90-day low: €1.75

NantHealth, Inc. to Report Q3, 2020 Results on Nov 05, 2020

NantHealth, Inc. to Report Q2, 2019 Results on Aug 08, 2019

NantHealth, Inc. Enhances Interoperability of the Navinet Open Platform with Expanded API Capabilities

NantHealth, Inc. Rolls Out Navinet AllPayer Platform Nationally

New 90-day low - €2.23

First half earnings released

NantHealth, Inc. to Report Q2, 2020 Results on Aug 06, 2020

NantHealth, Inc. (NasdaqGS:NH) acquired The OpenNMS Group, Inc. Cambridge Equities, LP.

Rendement voor aandeelhouders

Prijsvolatiliteit

Over het bedrijf

NantHealth, Inc. Samenvatting